Avanos Medical (NYSE:AVNS) Posts Earnings Results, Beats Expectations By $0.10 EPS

Avanos Medical (NYSE:AVNS) posted its quarterly earnings data on Wednesday. The company reported $0.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.12 by $0.10, Zacks reports. Avanos Medical had a negative net margin of 66.89% and a positive return on equity of 6.16%. The company had revenue of $177.80 million during the quarter, compared to the consensus estimate of $164.50 million. During the same period in the previous year, the firm posted $0.33 EPS. The firm’s revenue was up 4.3% compared to the same quarter last year. Avanos Medical updated its FY 2025 guidance to 0.850-0.950 EPS.

Avanos Medical Trading Down 2.8%

Shares of NYSE AVNS traded down $0.31 during midday trading on Wednesday, hitting $10.99. 604,049 shares of the company traded hands, compared to its average volume of 540,655. Avanos Medical has a 12-month low of $9.30 and a 12-month high of $21.12. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.58 and a current ratio of 2.64. The stock has a 50-day moving average price of $11.74 and a 200 day moving average price of $11.93. The firm has a market cap of $509.75 million, a P/E ratio of -1.09 and a beta of 1.19.

Wall Street Analyst Weigh In

Several analysts have weighed in on AVNS shares. Zacks Research raised shares of Avanos Medical to a “hold” rating in a research note on Tuesday, August 12th. Wall Street Zen downgraded shares of Avanos Medical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 9th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Avanos Medical in a research note on Tuesday, October 14th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Reduce”.

Insider Buying and Selling

In other news, Director Gary Blackford bought 40,000 shares of the company’s stock in a transaction dated Wednesday, August 13th. The shares were purchased at an average price of $10.99 per share, for a total transaction of $439,600.00. Following the completion of the purchase, the director owned 40,000 shares in the company, valued at approximately $439,600. This represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.64% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in AVNS. AQR Capital Management LLC lifted its stake in shares of Avanos Medical by 46.4% in the first quarter. AQR Capital Management LLC now owns 192,864 shares of the company’s stock worth $2,700,000 after buying an additional 61,095 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Avanos Medical by 4.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,955 shares of the company’s stock valued at $386,000 after purchasing an additional 1,121 shares during the period. Millennium Management LLC lifted its position in Avanos Medical by 508.3% during the first quarter. Millennium Management LLC now owns 547,740 shares of the company’s stock valued at $7,849,000 after purchasing an additional 457,703 shares during the period. Empowered Funds LLC lifted its position in Avanos Medical by 5.4% during the first quarter. Empowered Funds LLC now owns 162,182 shares of the company’s stock valued at $2,324,000 after purchasing an additional 8,348 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Avanos Medical by 17.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 140,810 shares of the company’s stock valued at $2,018,000 after purchasing an additional 20,541 shares during the period. Institutional investors own 95.17% of the company’s stock.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.